Leigh, Simon; Grant, Alison; Murray, Nicola; Faragher, Brian; Desai, Henal; Dolan, Samantha; Cabdi, Naeema; Murray, James B; Rejaei, Yasmin; Stewart, Stephanie; Edwardson, Karl; Dean, Jason; Mehta, Bimal; Yeung, Shunmay; Coenen, Frans; Niessen, Louis W; Carrol, Enitan D (2019) The cost of diagnostic uncertainty: a prospective economic analysis of febrile children attending an NHS emergency department. BMC Medicine, 17 (1). DOI: https://doi.org/10.1186/s12916-019-1275-z

Downloaded from: http://researchonline.lshtm.ac.uk/4652108/

DOI: 10.1186/s12916-019-1275-z

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
The cost of diagnostic uncertainty: a prospective economic analysis of febrile children attending an NHS emergency department

Simon Leigh 1,2*, Alison Grant 3, Nicola Murray 4, Brian Faragher 5, Henal Desai 6, Samantha Dolan 7, Naeema Cabdi 8, James B. Murray 9, Yasmin Rejaei 10, Stephanie Stewart 11, Karl Edwardson 12, Jason Dean 13, Bimal Mehta 14, Shunmay Yeung 15, Frans Coenen 16, Louis W. Niessen 17,18† and Enitan D. Carrol 1,2†

Abstract

Background: Paediatric fever is a common cause of emergency department (ED) attendance. A lack of prompt and definitive diagnostics makes it difficult to distinguish viral from potentially life-threatening bacterial causes, necessitating a cautious approach. This may result in extended periods of observation, additional radiography, and the precautionary use of antibiotics (ABs) prior to evidence of bacterial foci. This study examines resource use, service costs, and health outcomes.

Methods: We studied an all-year prospective, comprehensive, and representative cohort of 6518 febrile children (aged < 16 years), attending Alder Hey Children’s Hospital, an NHS-affiliated paediatric care provider in the North West of England, over a 1-year period. Performing a time-driven and activity-based micro-costing, we estimated the economic impact of managing paediatric febrile illness, with focus on nurse/clinician time, investigations, radiography, and inpatient stay. Using bootstrapped generalised linear modelling (GLM, gamma, log), we identified the patient and healthcare provider characteristics associated with increased resource use, applying retrospective case-note identification to determine rates of potentially avoidable AB prescribing.

Results: Infants aged less than 3 months incurred significantly higher resource use than any other age group, at £1000.28 [95% CI £82.39–£2993.37] per child, (p < 0.001), while lesser experienced doctors exhibited 3.2-fold [95% CI 2.0–5.1-fold] higher resource use than consultants (p < 0.001). Approximately 32.4% of febrile children received antibiotics, and 7.1% were diagnosed with bacterial infections. Children with viral illnesses for whom antibiotic prescription was potentially avoidable incurred 9.9-fold [95% CI 6.5–13.2-fold] cost increases compared to those not receiving antibiotics, equal to an additional £1352.10 per child, predominantly resulting from a 53.9-h increase in observation and inpatient stay (57.1 vs. 3.2 h). Bootstrapped GLM suggested that infants aged below 3 months and those prompting a respiratory rate ‘red flag’, treatment by lesser experienced doctors, and Manchester Triage System (MTS) yellow or higher were statistically significant predictors of higher resource use in 100% of bootstrap simulations.

(Continued on next page)

* Correspondence: Simon.leigh@liverpool.ac.uk
† Louis Niessen and Enitan D. Carrol contributed equally as senior authors to this work.
1 Institute of Infection and Global Health, University of Liverpool, 8 West Derby St, Liverpool L69 7BE, UK
2 Infectious Diseases Department, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Fever is a common cause of presentation to paediatric emergency departments (EDs) [1], accounting for ~20% of all visits [2], but despite its frequent occurrence, the aetiology of fever is diverse [3]. Most children with fever will suffer from self-limiting viral illnesses; however, viral, bacterial, and severe bacterial infections (SBIs) may result in almost identical clinical presentations in infants, making diagnosis based on presentation, history, and clinical judgement alone a difficult task.

While a clear focus of bacterial infection may be present with presentations of acute otitis media (AOM) or urinary tract infection (UTI), occult bacteremia can also occur in children who appear otherwise well, and fever without focus is a common presentation, particularly so in those aged <36 months [4–6]. However, occurring in as few as 1% of febrile children [4, 5], these ‘hidden’ bacterial infections represent a needle in the haystack, and the challenge for clinicians is to accurately identify children at risk of bacterial infections. While it is possible that they may resolve spontaneously, for those in whom they do not, life-threatening and potentially life-changing complications can develop [4, 7, 8], with adverse outcomes in each survivor of severe meningococcal disease resulting in lifelong treatment costs of ~£1.3m [9].

As a result, a cautious stepped approach to the management of the febrile child is common, characterised by extended periods of observation, investigations, radiography, and the precautionary use of antibiotics, often prior to definitive evidence of bacterial foci [10]. Unfortunately, such interventions are invasive, can be painful, and are likely to prolong a child’s visit to the ED, contributing to extended ED waiting times and driving the use of scarce ED healthcare resources.

The test currently providing the greatest degree of certainty in diagnosing invasive bacterial infections, the blood culture, typically takes 12–48 h to provide results, has a sensitivity of just 30–40% [11], and a significant false positive rate due to contamination with commensal bacteria from the skin and mucosal surfaces [12]. This limits the diagnostic utility of the blood culture to clinicians required to make decisions concerning the management of the febrile child in real time, which in turn increases the importance of sufficient observation time, blood/urine investigations, and clinical judgement.

With the potential over-treatment of febrile children on the one hand and the prospect of failing to identify potentially life-threatening SBIs on the other, a lack of timely and reliable indicators of febrile aetiology, coupled with a natural tendency for risk aversion when treating children, has resulted in a substantial financial burden to healthcare systems worldwide. However, to date, just a handful of studies, predominantly USA based and conducted between 6 and 25 years ago in young children, have examined the economic impact of paediatric febrile illness [13–16].

Using a bottom-up time-driven and activity-based costing model (TDABC), the aims of this research were to (1) estimate the economic impact of managing febrile illness episodes in children of all ages and presenting complaints, in an NHS paediatric ED setting; (2) identify how management practices and costs vary with factors including patient age, and the experience of treating clinicians; and (3) provide insights regarding where any diagnostic advances currently under development, including molecular diagnostics, protein biomarkers, and point-of-care (POC) testing technologies, are likely to yield the greatest clinical and socioeconomic value, by reducing clinical uncertainty increasing confidence to withhold antibiotics.

Methods

Participants and methods

This study applies time-driven activity-based costing (TDABC), a bottom-up approach to healthcare costing, which maps pathways observed during routine clinical practice, identifies all points and durations of interaction therein, and assigns time-dependent costs to each constituent. The costs of non-time-dependent activities, including tariff-based ancillary investigations, are subsequently added to provide a representative activity-weighted cost per completed treatment episode.

A total of 8552 consecutive febrile children, with a temperature above 38 °C at presentation or below 38 °C with an unverified parent-reported history of fever up to 3 days previous, were prospectively identified. All children visited Alder Hey Children’s NHS Foundation Trust, a large paediatric specialist care provider in the North West
of England, between 1 September 2012 and 31 August 2013. Children were excluded (1) if data concerning key components of their stay, including the treatments provided, or healthcare personnel seen, were missing or incomplete or (2) if there were pre-existing medical conditions likely to modify ED care pathways from those of the average ‘otherwise well’ patient, including paediatric oncology patients.

A schematic of the clinical pathway used for this study is provided in Fig. 1. Children were initially seen by a qualified ED nurse who conducted an initial evaluation, using the Manchester Triage System (MTS) [17]. MTS assessments follow a flow chart based on the patient’s reason for contacting the ED. The chart begins by identifying possible criteria indicating life-threatening conditions for the patient, and if none of these conditions are present, the nurse continues along the flow chart asking questions until the nurse assigns the patient an appropriate category. The nurse’s experience can contribute to the assessment, but on the other hand, the risk of the nurse missing serious conditions is reduced because the flow chart forces the nurse to ask key questions and make vital inquiries. Children were triaged as green ‘standard’, yellow ‘urgent’, orange ‘very urgent’, or red ‘immediate attention’. For several children, borderline ‘yellow/red’ or ‘orange/red’ categories were applied. This was a result of uncertainty during triage, and such children had their MTS classification amended with increased or reduced urgency following a second opinion with a nurse or clinician.

Diagnostic categories, defined as definite bacterial, probable bacterial or bacterial syndrome with low/no inflammatory markers, definite viral, probable viral, and viral syndrome with no/high inflammatory markers were collectively defined as ‘bacterial aetiologies’, while definite viral, probable viral, and viral syndromes with no/high inflammatory markers were collectively defined as ‘viral aetiologies’. Like other studies [19], the prescription of antibiotics for patients with anything other than a bacterial aetiology of fever was, for this study, defined retrospectively as ‘potentially avoidable’.

Because time stamps documenting the duration of contact with healthcare personnel for various treatments and investigations are not routinely collected as part of NHS electronic patient records, these were imputed in one of two ways. Firstly, estimates were provided by staff actively involved in the provision of ED care. Secondly, prospective time-in-motion data were collected for a representative cohort of 71 febrile children presenting to Alder Hey Children’s NHS Foundation Trust ED between January 6 and February 12, 2017. Four 5th-year medical students collected the data by ‘shadowing’ patients reporting to the book-in desk with fever as a symptom. Additionally, any patients suspected of fever by clinical teams (such as the nurse performing an initial visual assessment) were additionally identified. The researchers followed patients through the ED, documenting all points of interaction with healthcare professionals using a stopwatch and a pre-designed case report form. Data were collected in four hourly blocks during the day (8 a.m.–4 p.m.), evening (4 p.m.–12 a.m.), and early morning (12 a.m.–4 a.m.), 7 days a week. All children with a suspected fever were observed from the point of visual assessment, and their experience in the ED, timed using a stopwatch and documented in Microsoft® Excel. For any events which were not observed during implementation of the

---

![Fig. 1 Clinical pathway of paediatric febrile illness used for patient-level costing](image-url)
time-in-motion study, including clerical and administrative tasks such as writing up patient notes, these were estimated following a Delphi panel approach. In all such cases, a number of estimates were obtained and the average time was used because tasks, such as inserting a cannula for example, can be expected to take varying lengths of time depending upon factors such as experience, co-operation of the child, state of hydration, or vascular filling. All timings used are provided in Table 1.

**Unit costs**

Hourly salaries for healthcare personnel were provided by the patient-level costing department at the Trust. Except for clinicians, salaries for those working either (1) at the weekdays between 7 p.m. and 7 a.m. or (2) at the weekend had their hourly rate increased in line with NHS guidance on working unsocial hours [20]. Costs for non-time-driven activities, including laboratory-based investigations, were obtained from the Trust’s finance department and NHS reference costs 2015/16 [21].

Pharmaceuticals were assigned unit costs from the British National Formulary. As data concerning the precise antibiotics provided to patients were not available, we assumed that antibiotic prescribing was in line with the recommendations provided within NICE CG160 [22]. Namely, where intravenous (IV) antibiotics were prescribed, both a third-generation cephalosporin (cefotaxime, ceftriaxone) and an anti-listeria agent were provided (amoxicillin, ampicillin) for infants under 1 month, and a third-generation cephalosporin alone if more than 1 month. In cases of empiric IV antibiotic therapy, it was assumed that a third-generation cephalosporin directed against *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Escherichia coli*, *Staphylococcus aureus*, and *Haemophilus influenzae* type b was provided. Where oral antibiotics were prescribed, it was assumed that amoxicillin or cephalaxin was provided as per local antimicrobial guidance.

Costs incurred during inpatient stay were obtained from NHS reference costs 2015/16. The tariff HRG PW20C (paediatric fever of unknown origin, CC score = 0) was utilised to reflect a 3-day short stay inpatient admission. As children could be admitted for anywhere between 1 and 72 h under the reference tariff, this figure was divided through by 72 and multiplied by the number of hours of inpatient admission. Patients who exceeded the 3-day limit incurred an excess bed day charge which was applied from the fourth day until discharge [21]. Finally, indirect costs were estimated for each patient, using the ‘full absorption approach’. This included the anticipated use of facilities, such as toilets, and the time of administrative staff typing up and sending discharge notes to the patient’s general practitioners. Societal costs, including parental absence from work, and children’s absence from school were not included, as the analysis was conducted from a healthcare provider perspective. Due to the short time frame of the analysis, costs were not discounted. All unit costs were in 2017 prices and are provided within Table 1.

**Outcomes and statistical analysis**

We present summary statistics to describe the characteristics of participants. Categorical variables were summarised by frequency and percentage, while continuous variables were reported as mean, standard deviation (SD), median, interquartile range (IQR), and minimum and maximum values. Our primary outcome was the ‘cost per completed febrile illness episode’, with an ‘episode’ defined as the period from booking in to the ED to final discharge, enabling the possibility for re-attendances to be included. We additionally performed sub-group analyses to account for patient and healthcare provider heterogeneity. As our primary outcome data were both non-normally distributed, and characterised by sub-groups of unequal size, the Kruskal-Wallis test was applied to assess statistical significance, with Dunn’s post hoc pairwise comparison (adjusted by the Holm FWER method) used to determine where significant differences were present. Results were reported as *p* values and considered statistically significant at the standard 5% level. Multivariate regression analysis using a generalised linear model (GLM) was performed to estimate conditional mean health expenditure and identify covariates associated with increased healthcare utilisation. Because several prior studies have demonstrated that the gamma family with a log error link is not only robust, but also the most commonly applied approach in healthcare cohorts in which positive and skewed healthcare costs are

---

**Table 1** Staff time associated with components of the paediatric febrile illness pathway

| Activity                                      | Mean duration (min) |
|-----------------------------------------------|---------------------|
| Triage time (nurse)*                         | 4.5                 |
| Clinician consultation time (MTS green)*     | 16.2                |
| Clinician consultation time (MTS yellow)*    | 19.4                |
| Clinician consultation time (MTS orange)*    | 21.1                |
| Clinician consultation time (MTS red)*       | 22.7                |
| Clinician time—writing up patient notes*     | 10                  |
| Order blood/urine culture (clinician)*       | 10                  |
| Arrange X-ray (clinician)*                   | 6                   |
| Book patient into the ED (receptionist)*     | 2                   |
| Refer patient to other specialties (clinician)* | 20                 |
| Insert cannula (clinician)*                  | 20                  |
| Provide antibiotics/other medicines (nurse)* | 5                   |
| Visual assessment triage (nurse)*            | 2                   |
| Interpret results of ancillary investigations (clinician)* | 10              |

*Collected during time-in-motion study

*Estimate provided by ED consultants*
guaranteed [23, 24], our analysis also assumed a gamma error distribution with log link.

Finally, because all timings employed within the TDABC were estimates, and therefore subject to one or more of (1) sampling bias, (2) Hawthorne effects, or (3) reporting bias, a distribution of credible times for each patient interaction with healthcare personnel was used in the time-driven and activity-based costing, to reflect the uncertainty inherent to sampling. For all parameters contained within the time-driven and activity-based costing, continuous variables (time in consultation with clinician, days spent as inpatient) were randomly sampled from gamma distributions as explained by Briggs [25]. Dichotomous variables (percentage of triage assessments performed by band 5/6 nurses) were sampled from representative beta distributions constructed from the sample data available, as explained in previous work by Briggs et al. [26]. For estimates reliant on expert

| Table 2 Unit costs by component of paediatric febrile illness pathway | Item | Unit cost |
|---|---|---|
| **Investigations (per test)** | Amylase | £6.00 |
| | Bacterial PCR | £158.00 |
| | Bilirubin | £6.00 |
| | Biochemistry profile | £8.00 |
| | Blood albumin | £6.00 |
| | Blood glucose test | £6.00 |
| | Blood culture | £35.00 |
| | Blood gas$ | £7.00 |
| | Blood taken | £3.00 |
| | Calcium profile | £7.00 |
| | Clotting screen | £5.00 |
| | Creatinine | £6.00 |
| | CRP | £6.00 |
| | CSF | £6.00 |
| | CT scan (head) | £201.00 |
| | ECG | £33.00 |
| | ENT swab | £19.00 |
| | ESR | £4.00 |
| | FBC | £3.00 |
| | Glandular fever screen | £4.00 |
| | Group and save | £12.00 |
| | LFTs | £7.00 |
| | Magnesium | £6.00 |
| | Malarial parasite test | £21.00 |
| | Measles PCR | £55.00 |
| | Meningo pneumo PCR | £25.00 |
| | Meningococci screen | £6.00 |
| | Mycoplasma SER | £23.00 |
| | Pertussis swab | £9.00 |
| | Phosphate | £6.00 |
| | Rapid Strept test | £9.00 |
| | Renal profile | £46.00 |
| | Respiratory PCR | £117.00 |
| | RSV screen | £12.00 |
| | Ultrasound | £55.00 |
| | Urinalysis$ | £8.00 |
| | Urine albumin | £6.00 |
| | Urine culture$ | £8.00 |
| | Urine dipstick$ | £6.00 |
| | Urine sample | £8.53 |
| | Virus PCR | £56.00 |
| | X-ray | £46.00 |

---

**Table 2 Unit costs by component of paediatric febrile illness pathway (Continued)**

| Item | Unit cost |
|---|---|
| **Antibiotics (per dose/course)** | Amoxicillin 125 mg (suspended)* | £1.16 |
| | Amoxicillin 125 mg (IV)* | £4.34 |
| | Amoxicillin 250 mg (susp.)* | £1.33 |
| | Cefotaxime 195 mg (IV)* | £0.48 |
| | Cefotaxime 575 mg (IV)* | £0.66 |
| **Nurse time (per hour)** | Band 5 | £15.43 |
| | Band 6 | £18.95 |
| | Band 7 | £22.50 |
| | Band 8a | £27.39 |
| **Doctor time (per hour)** | FY1/FY2 | £24.24 |
| | ST1-3 | £30.79 |
| | APNP | £27.39 |
| | Registrar | £39.02 |
| | Consultant | £76.11 |
| **Referral to other specialties** | Surgery | £178.55 |
| | Medicine | £272.74 |
| | ENT | £146.92 |
| | Neuro | £411.78 |
| **Inpatient admission** | Short stay (HRG PW20C, 3 days non-elective stay)$ | £1712 |
| | Excess bed day charge$ | £462 |

Unit costs provided by Alder Hey Finance Team unless otherwise stated
*NHS Reference costs 2016
*British National Formulary 2017
opinion, which were not observed during the time-in-motion study due to a low frequency of occurrence, uniform distributions were sampled in the absence of information concerning the true sample mean and variance. In choosing this distribution, we combined and ranked response data from all healthcare professionals (of varying roles and experience) surveyed, to define lower and upper limits or ‘bounding’ criterion. Once responses were provided, respondents were informed of responses by other respondents to gauge their belief in the credibility of different responses and ensure that the distributions utilised were plausible. GLM regression modelling was subsequently replicated for 100 bootstrapped costing datasets randomly utilising parameter values from all plausible distributions, for all variables, to assess the sensitivity of the primary outcome, the cost per febrile illness episode, and the resulting GLM coefficients, to changes in the values of underlying input parameters. Details of all distributions utilised are provided in Table 3. All analyses were performed using STATA 14 (StataCorp LP, USA) and Microsoft Excel (Redmond, WA).

Table 3 Distributions used for probabilistic sensitivity analysis

| Parameter                                      | Distribution       |
|------------------------------------------------|--------------------|
| Time (hours)                                   |                    |
| Nurse triage                                   | Gamma (4.69, 0.01) |
| Proportion performed by band 6 nurses          | Beta (16, 55)      |
| Proportion performed by band 5 nurses          | 1-Beta (16, 55)    |
| Clinical consultation                           | Gamma (3.9, 0.04)  |
| Clinician writing up patient notes             | Uniform (1, 20)    |
| Arrange blood/urine culture                    | Uniform (1, 25)    |
| Arranging X-ray                                | Uniform (1, 30)    |
| Receptionist booking patient in                | Uniform (1, 5)     |
| Clinician arranging referral                    | Uniform (1, 25)    |
| Clinician cannulating child                    | Uniform (5, 35)    |
| Nurse providing antibiotics to child           | Uniform (1, 10)    |
| Visual assessment by nurse                     | Uniform (0.5, 5)   |
| Days spent as inpatient (if admitted)          | Gamma (3.72, 1.03) |
| Salary (cost/hour)                             |                    |
| Nurse (band 5)                                 | Uniform (13.36, 17.5) |
| Nurse (band 6)                                 | Uniform (16.14, 21.77) |
| Nurse (band 7)                                 | Uniform (19.34, 25.67) |
| Nurse (band 8a)                                | Uniform (24.8, 29.99) |
| Foundation year doctor                         | Uniform (22.5, 26) |
| ST1-3                                          | Uniform (27, 30.8) |
| APNP                                           | Uniform (24.8, 29.99) |
| Registrar                                     | Uniform (36, 41)   |
| Consultant                                     | Uniform (64.8, 87.4) |

Results

Descriptive statistics

Eight thousand five hundred fifty-two individual ED attendances were identified over the study period, with 2034 excluded from the analysis due to incomplete data or failing to meet our inclusion criteria. This resulted in a complete dataset of 6518 observations (Table 4). There was no significant difference in observable characteristics between those included and excluded, including but not limited to age, final diagnoses, MTS classification, and temperature.

The mean (median) age of children included was 3.28 (2.17) years, with 53.5% male and 46.5% female. At presentation, 47.52% of children were triaged as green ‘low risk’ cases using the Manchester Triage System (MTS) [17], 8.88% as yellow, 0.17% as yellow/red, 17.06% as orange, 23.03% as orange/red, and 0.39% as red (high risk). MTS classifications were not recorded in 2.9% of patients. Most patients (66.32%) were treated by specialty doctors (ST1-3), followed by registrars or ST4–8 (22.05%), consultants (7.99%), APNPs (2.73%), and Foundation year 1 and 2 doctors (0.91%). The mean (median) time was 15.3 (14.7 min) between booking and triage, 67.9 (52 min) between triage and clinical consultation, and 68.4 (70.6 min) between consultation and discharge. Total mean (median) time in the ED was 151.6 min (81.3 min). Approximately 6.46% of patients were admitted as inpatients, 1.42% of which for a single day, 29.78% 2 days, 21.51% 3 days, and 47.28% > 4 days.

Determinants of patient-level costs

Table 5 provides details of patient-level resource use and costing. Those aged 0–3 months exhibited a mean treatment cost of £1000.28, [95% CI £82.89–£2993.37], over six-fold higher than the least costly group, aged 3–6 years, (£158.97 [95% CI £20.43–£1596.43]). Use of blood cultures (p = 0.0312), urine samples, inpatient admission rates, and inpatient length of stay (p = 0.0001) were all statistically significantly increased for those aged 0–3 months, versus all other age groups, as shown in Table 6.

The distribution of MTS classifications was approximately equal across all age groups, except for those aged 0–3 months, 74.41% of which were triaged as yellow or higher. As expected, overall healthcare expenditure increased with increasing MTS severity, from £121.78 per patient (green), £424.43 (yellow), £487.16 (orange), and £549.42 (red), the majority of which as a direct result of increasing rates of inpatient admission. A one-step increase in triage category, from green to yellow, resulted in a 422% increase in inpatient admission, a 19.6% increase in length of stay for those admitted, and a 391% increase in use of blood cultures. In terms of final diagnoses, bacterial infections were most commonly observed in those aged 0–3 months (15.5%), 3–6 months...
### Table 4 Descriptive statistics of the study participants

|                        | Mean (SD) | Median (IQR) | Min     | Max     |
|------------------------|-----------|--------------|---------|---------|
| Age                    | 3.28 (3.09)| 2.17 (3.5)   | 4 days  | 15.98 years |
| Gender male (freq)     | 53.5% (3484) | –            | –       | –       |
| Temperature            | 38.7 (1.07) | 38.6 (1.7)   | 35      | 41.4    |
| Respiratory rate (bpm) | 29.95 (9.23) | 28 (8)       | 14      | 188     |
| Pulse (bpm)            | 138.7 (25.98) | 138 (37)    | 22      | 250     |
| Manchester Triage Scale (MTS) classification |          |              |         |         |
| MTS green (freq)       | 47.52% (3097) | –            | –       | –       |
| MTS yellow (freq)      | 8.88% (579)   | –            | –       | –       |
| MTS yellow/red (freq)  | 0.17% (11)     | –            | –       | –       |
| MTS orange (freq)      | 17.06% (1112) | –            | –       | –       |
| MTS orange/red (freq)  | 23.03% (1501) | –            | –       | –       |
| MTS red (freq)         | 0.39% (27)     | –            | –       | –       |
| MTS not recorded (freq)| 2.9% (191)     | –            | –       | –       |
| Timings                |            |              |         |         |
| Time between booking and triage (min) | 15.3 (14.7) | 11 (18)      | 0       | 71      |
| < 10                   | 47.8%       |              |         |         |
| 11–20                  | 24.1%       |              |         |         |
| 21–40                  | 20%         |              |         |         |
| 41–60                  | 5.6%        |              |         |         |
| > 61                   | 2.5%        |              |         |         |
| Time between triage and consultation (min) | 67.9 (52) | 55 (65)      | 0       | 609     |
| < 30                   | 26.9%       |              |         |         |
| 31–60                  | 27.7%       |              |         |         |
| 61–120                 | 30.8%       |              |         |         |
| 121–180                | 11.4%       |              |         |         |
| 181–240                | 2.6%        |              |         |         |
| > 240                  | 0.6%        |              |         |         |
| Time in ED post consultation (min) | 68.4 (70.6) | 45 (72)      | 0       | 630     |
| < 30                   | 43.5%       |              |         |         |
| 30–60                  | 15.1%       |              |         |         |
| 61–120                 | 24.8%       |              |         |         |
| 121–180                | 9.7%        |              |         |         |
| > 181                  | 7%          |              |         |         |
| Total time in ED (min) | 151.6 (81.3) | 135 (98)    | 16      | 729     |
| < 60                   | 8.3%        |              |         |         |
| 61–120                 | 32.7%       |              |         |         |
| 121–240                | 46.9%       |              |         |         |
| 241–360                | 9.6%        |              |         |         |
| > 361                  | 2.5%        |              |         |         |
| Inpatient length of stay (days) |          |              |         |         |
| Not hospitalised       | 93.51%      |              |         |         |
| 1–3                    | 3.42%       |              |         |         |
| 4–7                    | 2.43%       |              |         |         |
| 8+                     | 0.63%       |              |         |         |
(11.03%), and 10–16 years (11.74%); however, the only significant difference was when comparing these groups to those aged 1–3 years (4.6%), \( p < 0.05 \). Those with bacterial aetiologies of fever exhibited over threefold higher management costs than those with viral aetiologies (£988.19 vs. £294.52).

**Antibiotic prescribing patterns**
Approximately 32.4% of febrile children were prescribed antibiotics, of whom 7.05% were retrospectively diagnosed with bacterial aetiology of fever. Approximately 14.9% of patients were retrospectively classified as having inflammatory, 10.8% as trivial, and 6.6% as viral aetiologies of fever (probable, definite and viral syndromes) were prescribed potentially avoidable antibiotics, if a means of distinguishing these from bacterial causes of infection has been available (Table 7). Analysing children with viral causes of fever who were triaged as MTS green or yellow (those not deemed to require very urgent or immediate care), those receiving antibiotics spent an additional 53.9 h as inpatients (57.1 vs. 3.2 h) compared to children with viral aetiologies of fever, triaged MTS green or yellow, who were not prescribed antibiotics. This resulted in a 9.9-fold increase in management costs for those who received potentially avoidable antibiotics (£1392.30 vs. £140.10) as shown in Table 8, the majority of which attributable to the costs of inpatient or short stay beds for observation.

**Determinants of increased healthcare expenditure during paediatric febrile episodes**
Based on generalised linear modelling, compared to the reference group of those aged 1–3 years, those aged 0–3 months experienced a 3.6-fold [95% CI 2.59–4.85-fold, \( p < 0.0001 \)] increase in healthcare resource use. The presence of a NICE NG51 respiratory rate red flag [27] increased costs by 72.1% (\( p < 0.0001 \)) (Table 6). Other factors associated with increased resource use included treatment by Foundation year 1/Foundation year 2 (FY1/FY2) doctors, which were increased 3.19-fold, relative to the consultant reference group, \( p < 0.0001 \). When considering only non-urgent children, triaged as green using the MTS, FY1/FY2 doctors exhibited a 7.98-fold increase in costs of management, relative to consultants (\( p < 0.0001 \)). FY1/FY2 doctors recorded the highest rates of inpatient admission, ancillary investigations, and referring children to other specialties. Comparing resource use for FY1/FY2 doctors working out of hours and those working during regular hours, where the availability of ancillary investigations may be reduced, there was no significant difference (\( p = 0.9626 \)). Factors including male gender and being treated by an APNP were shown to reduce costs by 15.1% (\( p = 0.0241 \)) and 42.7% (\( p = 0.0112 \)) respectively, as shown in Table 9.

Increasing clinical severity, as proxied by increasing MTS classifications, resulted in significant cost increases of 138.2% (2.38-fold), 185.7% (2.85 fold), and 199.2% (2.99-fold) respectively compared to children triaged as green (all \( p < 0.01 \)). As such, we performed independent GLM regressions for three MTS groups (green, yellow, and orange/red), to account for the possibility that severity of illness may have an important role in determining overall resource use. Similar to the results when pooling children of all severities, those demonstrated in Fig. 2 highlight the consistent importance of ages (<6 months, 10–16 years), prompting a NICE respiratory rate red flag [27], and being treated by an FY1 or FY2 doctor, suggesting that these are key drivers of increased resource use when managing paediatric febrile illness after taking clinical severity into account.

**Sensitivity analysis**
Our findings were insensitive to changes in the values of our input parameters. Following the Monte Carlo simulation and re-running our generalised linear models on 100 bootstrapped datasets, the coefficients listed in Table 10 were obtained. Children triaged as MTS yellow or above, those prompting a NICE NG51 respiratory rate red flag, and those treated by an FY1/FY2 doctor, and treatment of children...
Table 5 Health service costs of paediatric febrile illness by sub-group

| Age          | Number | Mean     | Std. dev | 95% CI       | Median | IQR       | p value* |
|--------------|--------|----------|----------|--------------|--------|-----------|----------|
| 0–3 months   | 129    | £1000.28 | £1469.98 | £82.39–£2993.37 | £76.65 | £1834.10 |          |
| 3–6 months   | 281    | £522.33  | £1737.66 | £122.08–£2123.51 | £33.63 | £55.70   |          |
| 6–12 months  | 1041   | £205.28  | £585.18  | £28.26–£734.39    | £51.29 | £21.50   |          |
| 1–3 years    | 2498   | £190.44  | £594.95  | £13.22–£643.89    | £51.64 | £21.60   |          |
| 3–6 years    | 1547   | £158.97  | £501.82  | £20.43–£1596.43   | £51.29 | £19.80   | p = 0.0001|
| 6–10 years   | 707    | £165.92  | £485.04  | £11.14–£843.02    | £52.98 | £20.70   |          |
| 10–16 years  | 315    | £408.32  | £1030.12 | £44.97–£2188.27   | £55.55 | £40.90   |          |

| Gender       |        |          |          |              |        |           |          |
|--------------|--------|----------|----------|--------------|--------|-----------|----------|
| Male         | 3482   | £210.17  | £600.23  | £38.45–£818.68 | £51.29 | £21.50    |          |
| Female       | 3036   | £238.90  | £835.77  | £14.13–£924.63  | £53.16 | £23.10    |          |

| NICE NG51 heart rate red flag [27] |        |          |          |              |        |           |          |
|-----------------------------------|--------|----------|----------|--------------|--------|-----------|----------|
| Yes                               | 2797   | £259.40  | £848.10  | £21.76–£1015.89 | £54.03 | £24.60    | p = 0.0001|
| No                                | 3721   | £196.59  | £604.38  | £18.36–£699.74  | £50.87 | £20.30    |          |

| NICE NG51 respiratory rate red flag [27] |        |          |          |              |        |           |          |
|------------------------------------------|--------|----------|----------|--------------|--------|-----------|----------|
| Yes                                      | 394    | £493.92  | £1035.52 | £89.16–£2011.32 | £54.03 | £24.60    | p = 0.0001|
| No                                       | 6124   | £196.59  | £604.38  | £18.36–£699.74  | £50.87 | £20.30    |          |

| Clinical grade                        |        |          |          |              |        |           |          |
|---------------------------------------|--------|----------|----------|--------------|--------|-----------|----------|
| APNP                                  | 178    | £109.52  | £312.67  | £12.74–£741.65 | £48.01 | £21.80    |          |
| Consultant                            | 521    | £315.13  | £1344.91 | £25.76–£1536.36 | £73.23 | £40.70    | p = 0.0001|
| FY 1 and 2                            | 59     | £731.78  | £913.38  | £97.91–£1125.77 | £327.98 | £49.90    |          |
| Registrar                             | 1437   | £731.78  | £913.38  | £97.91–£1125.77 | £327.98 | £49.90    |          |
| ST1-3                                 | 4323   | £199.68  | £615.00  | £12.51–£721.02  | £49.77 | £28.05    |          |

| Afterhours                            |        |          |          |              |        |           |          |
|---------------------------------------|--------|----------|----------|--------------|--------|-----------|----------|
| Yes                                   | 5798   | £222.22  | £726.36  | £14.77–£776.64 | £51.92 | £22.40    |          |
| No                                    | 720    | £234.19  | £664.61  | £11.96–£913.33 | £51.65 | £22.00    | p = 0.0018|

| MTS classification                    |        |          |          |              |        |           |          |
|---------------------------------------|--------|----------|----------|--------------|--------|-----------|----------|
| Green                                 | 3098   | £121.78  | £390.33  | £15.81–£400.93 | £49.43 | £19.05    |          |
| Yellow                                | 579    | £424.43  | £1027.90 | £340.99–£508.17 | £63.10 | £55.73    |          |
| Yellow/red                            | 10     | £85.71   | £95.24   | £71.73–£99.42   | £52.33 | £16.50    | p = 0.0001|
| Orange                                | 1112   | £487.16  | £1209.15 | £416.08–£558.24 | £68.86 | £77.05    |          |
| Orange/red                            | 1502   | £152.13  | £491.60  | £123.44–£170.56 | £51.84 | £17.20    |          |
| Red                                    | 26     | £549.42  | £813.99  | £236.47–£862.35 | £76.88 | £1165.85  |          |
| Not recorded                           | 191    | £292.01  | £966.43  | £154.93–£429.09 | £50.87 | £20.40    |          |

| Final diagnosis                       |        |          |          |              |        |           |          |
|---------------------------------------|--------|----------|----------|--------------|--------|-----------|----------|
| Bacterial infection/syndrome          | 460    | £988.19  | £1781.97 | £86.89–£2971.08 | £77.95 | £1757.35  |          |
| Viral infection/syndrome              | 1595   | £294.52  | £797.43  | £18.92–£1082.33 | £51.64 | £24.25    |          |
| Inflammatory infection/syndrome       | 74     | £582.58  | £1302.26 | £37.60–£1516.05 | £63.44 | £1140.65  | p = 0.0001|
| Other or trivial infection            | 130    | £390.06  | £786.27  | £22.34–£1243.30 | £64.04 | £187.15   |          |
| Unknown cause                         | 4259   | £103.06  | £286.52  | £12.40–£633.87  | £51.29 | £18.60    |          |

*Kruskal-Wallis test

aged 0–3 months, 3–6 months, or 10–16 years respectively, were statistically significant predictors of increased healthcare costs in 100% of simulations. Conversely, the cost savings associated with male gender and treatment by an APNP remained significant in just 8% and 28.3% of simulations respectively.
Discussion

This study reports the largest comprehensive, prospective observational study to date, assessing the economic implications of diagnostic uncertainty when managing paediatric febrile illness, in those aged 0–16 years, in an ED setting. In a full cohort analysis on the management of this highly common condition, we demonstrate that the healthcare resources required to manage this condition are both significant and subject to extensive variation, some of which can be explained by the presence of certain patient and healthcare provider characteristics. Infants aged 0–6 months (particularly those aged 0–3 months), those triaged as MTS yellow or above, and those managed by lesser experienced clinicians (FY1 and FY2) required significantly greater resources in the ED. This was primarily a result of increases in observation time for patients and inpatient length of stay, the latter particularly prominent in those receiving antibiotics. In cases of MTS green and yellow viral infections, where antibiotics were potentially avoidable, provided more sensitive and prompt diagnostics had been available at this time, costs increased 9.9-fold (95% CI 6.48–13.2-fold). This was equivalent to an additional £1352.20 spend per patient (all patients pooled), rising to £2363 for infants aged less than 3 months.

Our study had several strengths. We included more than 6500 febrile children over all seasons during a 1-year period, and by applying TDABC methodology, we could achieve significant detail regarding actual resource use. This resulted in an inclusive and representative estimate of the economic impact of paediatric febrile illness to NHS EDs. Capturing model input data using a prospective time-in-motion approach provided confidence regarding the time requirements of essential components of care in the patient pathway. Data regarding these patient touchpoints are not currently available in

Table 6 Health service utilisation by patient age and MTS score

| Age          | Inpatient | Length of stay (days) | Any test | Blood culture | X-ray | Urine sample | Review by consultant |
|--------------|-----------|-----------------------|----------|---------------|-------|--------------|----------------------|
| 0–3 months   | 34.11%    | 5.67                  | 51.16%   | 28.70%        | 9.30% | 39.53%       | 10.07%               |
| 3–6 months   | 15.66%    | 5.34                  | 40.92%   | 11.03%        | 12.10%| 32.74%       | 5.69%                |
| 6–12 months  | 6.34%     | 3.83                  | 31.98%   | 2.01%         | 9.12% | 23.24%       | 8.64%                |
| 1–3 years    | 5.36%     | 4.05                  | 29.74%   | 2.52%         | 10.88%| 18.37%       | 7.64%                |
| 3–6 years    | 4.01%     | 4.02                  | 28.70%   | 3.03%         | 9.43% | 13.70%       | 8.14%                |
| 6–10 years   | 4.53%     | 3.78                  | 34.08%   | 3.67%         | 9.61% | 17.25%       | 8.76%                |
| 10–16 years  | 7.96%     | 4.73                  | 42.22%   | 8.88%         | 10.15%| 15.87%       | 7.3%                 |
| p value      | 0.0001§   | 0.0001*               | 0.0001§  | 0.0001§       | 0.5370§| 0.0001§      | 0.1342§             |

MTS classification

| MTS classification | Inpatient | Length of stay (days) | Any test | Blood culture | X-ray | Urine sample | Review by consultant |
|--------------------|-----------|-----------------------|----------|---------------|-------|--------------|----------------------|
| Green              | 2.61%     | 3.88                  | 24.59%   | 1.51%         | 5.68% | 16.17%       | 8.06%                |
| Yellow             | 13.64%    | 4.64                  | 43.52%   | 7.42%         | 11.91%| 23.48%       | 9.32%                |
| Orange             | 17.27%    | 4.23                  | 44.6%    | 10.07%        | 23.2% | 19.15%       | 8.45%                |
| Red                | 30.77%    | 2.63                  | 26.92%   | 15.38%        | 11.53%| 11.53%       | 23.07%               |
| p value            | 0.0001§   | 0.0001#               | 0.0001#  | 0.0001#       | 0.5370§| 0.0001§      | 0.1342§             |

#Mean length of stay among those admitted for at least 1 day
*Kruskal-Wallis test
§Chi-squared test

Table 7 Antibiotic prescribing rates differentiated by age and final diagnosis

| Receiving antibiotics | Total (%) | 0–3 months (%) | 3–6 months (%) | 6–12 months (%) | 1–3 years (%) | 3–6 years (%) | 6–10 years (%) | 10–16 years (%) | p value# |
|-----------------------|-----------|----------------|----------------|-----------------|---------------|---------------|----------------|----------------|----------|
| All                   | 32.4 27.9 | 24.2 24.6      | 24.3 31.9      | 37.7 34.5      | 40.3          | 0.0001        |
| Bacterial             | 89.6 85   | 96.8 84.3      | 93.6 98.9     | 87.7 89.3      | 91.9          | 0.3610        |
| Viral                 | 6.6 20.8  | 10 3.2        | 9.4 4         | 2.60 5.7       | 0.0001        |
| Inflammatory          | 14.9 0    | 0 9.5        | 17.2 23.1    | 12.5 0.9330    |
| Trivial               | 10.8 0    | 50 0         | 8.1 20        | 5.3 0.0820     |
| Unknown               | 36.4 17.3 | 19.2 25.5     | 35.7 43.3     | 42.2 48.1      | 0.0001        |

#Chi-squared test
published literature, and we believe this analysis has filled a gap which may subsequently be used for similar health economic analyses in the future.

Limitations of our study include the fact that presumed viral and bacterial aetiologies of fever were applied retrospectively; therefore, we lacked the benefit of clinical acumen and parental anxiety which could heavily influence the decision to prescribe antibiotics. While we made every effort to minimise bias when coding final diagnoses using the algorithm provided by Herberg et al. [18], there is a possibility that errors could have occurred, which may have affected conclusions regarding potentially avoidable antibiotics in the event of an incorrect diagnosis. However, following random sampling and checking of diagnoses, we believe the likelihood of this to be minimal given the level of detail provided and simplicity in using the diagnosis algorithm. Another potential limitation is the completeness of the dataset, with just under 24% of observations removed due to missing or incomplete data. While it was assumed that these

| Table 8 Treatment costs differentiated by age, final diagnosis, and antibiotic status |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Antibiotics given? | Viral | Trivial | Inflammatory | Bacterial |
|---------------------|-------|--------|-------------|----------|
| Yes | No | Yes | No | Yes | No | Yes | No |
| All* | £1392.30 | £140.10 | £324.49 | £224.54 | £185.08 | £669.86 | £755.03 | £747.43 |
| 0–3 months | £2842.60 | £479.65 | N/A | £113.81 | N/A | £50.87 | £2476.96 | £2419.07 |
| 3–6 months | £1969.38 | £142.81 | £50.39 | £334.50 | N/A | £65.92 | £1078.39 | £60.78 |
| 6–12 months | £2452.83 | £159.57 | N/A | £58.63 | N/A | £376.20 | £774.53 |
| 1–3 years | £867.02 | £151.09 | £2223.43 | £256.88 | £51.43 | £390.81 | £883.52 | £278.09 |
| 3–6 years | £1201.76 | £123.97 | £58.69 | £196.88 | £54.52 | £355.06 | £450.45 | £586.77 |
| 6–10 years | £1575.80 | £63.65 | £51.46 | £87.65 | £476.53 | £447.45 | £416.84 | £672.95 |
| 10–16 years | £2603.54 | £143.37 | N/A | £401.88 | £101.95 | £4842.32 | £1484.10 | £694.91 |
| *MTS green and yellow only

| Table 9 Determinants of healthcare resource use for paediatric febrile episodes |
|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
| Coefficient | Ln(β) | Exp (β) | 95% CI (β) low | 95% CI (β) high | p value |
|--------------------------|-------|--------|---------------|---------------|---------|
| 0–3 months | 1.265 | 3.543 | 2.589 | 4.85 | 0.001 |
| 3–6 months | 0.791 | 2.207 | 1.544 | 3.155 | 0.001 |
| 6–12 months | 0.171 | 1.186 | 0.924 | 1.524 | 0.180 |
| 3–6 years | -0.164 | 0.848 | 0.705 | 1.021 | 0.082 |
| 6–10 years | -0.046 | 0.954 | 0.738 | 1.235 | 0.724 |
| 10–16 years | 0.656 | 1.927 | 1.399 | 2.654 | 0.001 |
| Gender (male) | -0.163 | 0.849 | 0.736 | 0.978 | 0.024 |
| Time from book-in to triage | -0.005 | 0.994 | 0.990 | 0.999 | 0.013 |
| NICE HR | 0.034 | 1.034 | 0.894 | 1.197 | 0.644 |
| NICE RR | 0.543 | 1.721 | 1.289 | 2.299 | 0.001 |
| Time from triage to call in | -0.001 | 0.999 | 0.997 | 1.000 | 0.357 |
| APNP | -0.555 | 0.573 | 0.374 | 0.878 | 0.011 |
| FY1/FY2 | 1.161 | 3.193 | 2.017 | 5.055 | 0.001 |
| ST1-3 | -0.161 | 0.851 | 0.670 | 1.081 | 0.187 |
| Registrar | -0.068 | 0.933 | 0.719 | 1.212 | 0.608 |
| After hours** | 0.147 | 1.159 | 0.867 | 1.548 | 0.317 |
| Winter | -0.215 | 0.806 | 0.695 | 0.934 | 0.004 |
| MTS yellow | 0.868 | 2.382 | 1.905 | 2.979 | 0.001 |
| MTS orange | 1.049 | 2.857 | 2.397 | 3.405 | 0.001 |
| MTS red | 1.096 | 2.992 | 1.762 | 5.081 | 0.001 |

*Figures are exponentiated GLM (gamma, log) coefficients, interpreted as x-fold increases versus the reference group
*Reference group age = 1–3 years, reference group clinical grade = consultants, reference group MTS classification = green
**Between the hours of 6.30 p.m. and 8 a.m. Monday to Friday, and all-day Saturday, Sunday, and bank holidays
data were missing at random, we cannot be sure of this, and as such, we are unsure how the results may have differed if data for these 2034 children were available. While we made every effort to ensure a thorough approach to capturing NHS resource use, there were also instances where we likely underestimated costs. Our time-in-motion data did not capture information regarding additional consultations and advice from senior members of staff, which are likely to increase the costs of lesser experienced clinicians managing febrile children, nor did it include the societal costs of febrile illness borne by parents, including time off work, especially in the case of hospitalisation. Considering that new diagnostics may result in a reduction in antibiotic use, it is plausible that re-attendances or time observing patients in the department could increase, thereby potentially reducing the value to parents of improved diagnostics. The final limitation of our study concerns the generalisability of the findings to other settings, whether in the UK, Europe, or further afield. Our data were collected from a single site, and our analysis based on local prescribing protocols, as such, the economic value of improving the management of febrile illness in other settings, including the USA, where a more consultant-led approach may be more common, may differ from those demonstrated here.

Two previous studies have reported healthcare costs for managing children with SBIs, namely UTI [13] and meningitis [14]. Two studies reporting costs of management for children with fever of any cause [15, 16] have been performed in the USA, with data collected at least 5 years ago, in children aged < 3 years and < 90 days respectively, thereby limiting their generalisability. Additionally, one study conducted in Switzerland demonstrates the cost of illness associated with paediatric community-acquired pneumonia in 2010 [28]. However, no study prior to ours has assessed the resource implications of managing fever in a broad and representative cohort of all ages, diagnoses, and types of resource use in Europe.

The finding that infants (particularly those aged < 3 months) tended to require significantly greater ED resources may be explained by increased cautiousness and a lack of symptomatic information directly from the children themselves, when managing febrile infants. Despite most causes of fever in children being self-limiting, the fear of missing life-threatening infection in children with fever remains a persistent problem for clinicians, who have a natural tendency to be risk averse [29]. Commonly reported concerns among clinicians treating febrile children include suspected central nervous system damage (24%), seizures (19%), and death (5%) [30], manifesting in overly aggressive, and often, in hindsight, unnecessary treatment [31]. Additionally, the prevalence of invasive bacterial infections, bacteraemia and bacterial meningitis, is highest in the first 3 months of life, driving clinician behaviour towards a cautious approach in this high-risk group. Clinical
prediction rules, such as the Yale observation scale may be useful in these groups, particularly among those with less experience in ruling in/out serious bacterial infections; however, reliability in higher vs. lower income countries is variable, suggesting that these alone may not be enough to fill the diagnostic gap faced by the clinician managing paediatric febrile illness.

Though potentially avoidable antibiotic prescribing was lower in our cohort (6.6% viral, 10.8% trivial illness) than in similar studies based in the USA (36%) and Oxford, England (34%) [36], we found that antibiotic prescribing for those with viral causes of fever was highest in those aged 0–3 (20.8%), and 3–6 months (10%) supporting our finding of an increased tendency to be cautious when treating young febrile infants. This resulted in not only a substantial increase in ED resource use, but also likely increased inconvenience and distress to the children and parents involved, due to potentially unnecessary investigations and treatment. Furthermore, excess use of antibiotics is known to contribute to increasing rates of antimicrobial resistance (AMR) [37], an important component of both the clinical and economic impact of AB prescribing which we were unable to quantify in this analysis.

Given the paucity of published evidence, additional research examining the patient-centred and societal implications of current diagnosis and treatment practices when managing the febrile child would add considerable value for those looking to determine the true value of improved diagnostics, which may be capable of better targeting of scarce ED resources. Given the variable performance and accuracy of the MTS triage system in paediatric populations, we believe our finding that costs increased with MTS severity is noteworthy. Recent large-scale validation studies have highlighted the low reliability of the MTS in both younger [17] and older children presenting to the ED with fever [38], with an estimated 54% of children over-triaged when using the MTS [34]. In adult studies, over-triaging by just a single category, from green to yellow, has been shown to increase the use of electrocardiogram (ECG) and laboratory investigations by 261% and 148% respectively [39]. Similarly, in our study, children triaged as yellow experienced a 422% increase in inpatient stay, a 76.9% increase in ancillary investigations, and a 15.6% increase in review by consultants, versus those triaged as green. As the MTS categories yellow, orange, and red represent urgent, very urgent, and immediate attention respectively, these are the

### Table 10 Sensitivity analyses of determinants of healthcare costs for paediatric febrile episodes

| Category          | β (base-case)* | β (bootstrapped) Minimum | Maximum | Statistically significant* (%) |
|-------------------|----------------|--------------------------|---------|-------------------------------|
| 0–3 months        | 3.543          | 3.11                     | 2.16   | 3.92 (10.69%)                 | 100 |
| 0–6 months        | 2.207          | 2.08                     | 1.45   | 2.68 (21.55%)                 | 100 |
| 6–12 months       | 1.186          | 1.27                     | 1.00   | 1.54 (29.84%)                 | 38.38 |
| 3–6 years         | 0.848          | 0.88                     | 0.68   | 0.98 (15.77%)                 | 19.19 |
| 6–10 years        | 0.954          | 1.00                     | 0.74   | 1.18 (23.63%)                 | 0 |
| 10–16 years       | 1.927          | 1.81                     | 1.25   | 2.10 (8.98%)                  | 100 |
| Gender (male)     | 0.849          | 0.90                     | 0.78   | 0.99 (16.64%)                 | 8.08 |
| Time (book-in to triage) | 0.994  | 1.00                     | 0.99   | 1.00 (0.65%)                  | 16.16 |
| NICE HR           | 1.034          | 1.03                     | 0.89   | 1.12 (8.75%)                  | 0 |
| NICE RR           | 1.721          | 1.65                     | 1.19   | 1.99 (15.60%)                 | 100 |
| Time (triage to call in) | 0.999 | 1.00                     | 1.00   | 1.00 (0.13%)                  | 3.03 |
| APNP              | 0.573          | 0.99                     | 0.37   | 0.99 (72.91%)                 | 28.28 |
| FY1/FY2           | 3.193          | 3.29                     | 1.98   | 4.06 (27.11%)                 | 100 |
| ST1-3             | 0.851          | 0.90                     | 0.72   | 1.01 (18.17%)                 | 0 |
| REG               | 0.933          | 1.00                     | 0.76   | 1.12 (20.10%)                 | 0 |
| After hours       | 1.159          | 1.19                     | 0.90   | 1.47 (26.54%)                 | 2.02 |
| Winter            | 0.806          | 0.79                     | 0.68   | 0.89 (10.11%)                 | 98.99 |
| MTS yellow        | 2.382          | 2.27                     | 1.77   | 2.61 (9.59%)                  | 100 |
| MTS orange        | 2.857          | 2.89                     | 2.23   | 3.21 (12.43%)                 | 100 |
| MTS red           | 2.992          | 4.52                     | 1.95   | 6.87 (129.76%)                | 100 |
| Constant          | 164.8          | 143.50                   | 90.33  | 179.37 (8.84%)                | 100 |

Reference group age = 1–3 years, reference group clinical grade = consultants, reference group MTS classification = green

*Figures are exponentiated GLM (gamma, log) coefficients, interpreted as x-fold increases versus the reference group

*Proportion of 100 bootstrapped GLM regressions in which p value was < 0.05
groups with the highest probability of SBIs, we believe these are the groups where novel diagnostics should be targeted.

While we found evidence of an increase in healthcare utilisation among the least experienced clinicians (FY1/ FY2), just 0.9% of clinicians included in our study were FY1 and FY2 doctors. The results observed in this sample were therefore highly susceptible to bias through a lack of inter-clinician variability, and with a larger sample size may regress towards a lower mean. Additionally, although GLM analyses highlighted a 44.2% increase in time spent in the ED for those treated by FY1 and FY2 doctors when compared to consultants, this was likely due to the need to seek second opinions from more experienced colleagues, something which we were unable to attach costs to. This may also have been because lower acuity patients wait the longest and are more likely to be seen by lesser experienced doctors, as the sickest are re-directed to senior doctors. Because it is likely that any advances in diagnostics are likely to be heavily used by lesser experienced doctors, this could reduce times in the ED, but potentially still increase management costs. This is particularly true if the price of novel POC tests is high, as with multiplex PCR, which may cost the same as a day in the hospital when first released. The price of such tests can however be expected to decrease over time, resulting in savings over the longer term.

Conclusions
In conclusion, based on a comprehensive and representative sample of febrile children of varying age, presenting complaints, final diagnoses, and treating clinicians, this study has shown that the management of paediatric febrile illness in the ED poses a substantial financial burden. This is predominantly due to the impact of diagnostic uncertainty, which most often leads to increased observation time and inpatient admission. Children aged 0–6 months, those triaged as MTS yellow and above, and those managed by newly qualified doctors are the most likely to receive additional resources in the ED. After accounting for the severity of illness, precautionary antibiotic prescribing, particularly in younger low acuity children with viral illnesses, is associated with substantial increases in health service utilisation, predominantly because of increases in inpatient admissions. So far, information on potential shifts in infection epidemiology, such as an increase in healthcare-associated infections or reductions in vaccine-preventable infections or increases in invasive disease due to serotype replacement, are unlikely to affect our conclusions. Comparable settings in the UK and elsewhere will likely show similar patterns in resource use. Any advances in diagnostic capabilities, including molecular diagnostics, protein biomarkers, and POC tests would likely yield the potentially greatest efficiency gains in these groups of children, as among these the perceived risks of untimely diagnosis are greatest.

Abbreviations
95% CI: 95% confidence interval; AB: Antibiotic; AOM: Acute otitis media; APNP: Advanced paediatric nurse practitioner; CRP: C-reactive protein; ECG: Electrocardiogram; ED: Emergency department; FY1/FY2: Foundation year 1/Foundation year 2; GLM: Generalised linear model; IQR: Interquartile range; MTS: Manchester Triage System; NHS: National Health Service; NICE: National Institute for Health and Care Excellence; POC: Point of care; SBI: Serious bacterial infection; SD: Standard deviation; ST1-3: Specialised training years 1–3; TDABC: Time-driven and activity-based costing; USA: United States of America; UTI: Urinary tract infection

Acknowledgements
We thank the children and their parents for participating in the study, and ED staff for their considerable contribution to the study.

Funding
SL is funded by a studentship from the Institute of Infection and Global Health, The University of Liverpool and the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 668303 (PERFORM study (Personalised Risk assessment in Febrile illness to Optimise Real-life Management across the European Union)). The study sponsors had no involvement in the formation of the research questions nor the analysis itself.

Availability of data and materials
The data that support the findings of this study are available from the authors upon reasonable request.

Authors’ contributions
EDC and LN devised the study and will act as guarantors for the paper. AG supervised the collection of data. EH, NM, LH, JBM, NMOC, YR, SS, SD, and HD helped collect the data. SL, BF, and FC planned and performed all statistical analyses, with SL conducting all costings and data cleaning. JD collected the costing data, and KE collected the additional electronic patient data. SL wrote the first draft of the manuscript and revised and approved the final manuscript as submitted. All authors helped draft the manuscript and approved the final submitted version.

Ethics approval and consent to participate
Ethical approval was the study was granted by North West 9 Research Ethics Committee. REC reference number: 10/H1014/53. Parental consent was obtained prior to data collection.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Institute of Infection and Global Health, University of Liverpool, 8 West Derby St, Liverpool L69 7BE, UK. 2Infectious Diseases Department, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK. 3Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK. The Royal Liverpool University Hospital, Prescot St, Liverpool L7 8XP, UK. 4Medical Statistics Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK. 5Royal Derby Hospital, Uttoxeter Road, Derby DE22 3NE, UK. 6Royal Bolton Hospital, Minerva Road, Farnworth BL4 0JR, UK. 7School of Medicine, University of Liverpool, Cedar House, Liverpool L69 9GE, UK. 8Queen Elizabeth Hospital, Mindelsohn Way, Birmingham B15 2TH, UK. 9Pinderfields District General Hospital, Aberford Road, Wakefield WF1 4DG, UK. 10Wirral University Teaching Hospital, Arrowe Park Road, Wirral CH49 5PE, UK. 11Information Department, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK. 12Finance Department, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK. 13Emergency Department, Alder Hey Children’s NHS Foundation Trust, Eaton Road, Liverpool L12 2AP, UK. 14Department of
Clinical Research, MARCH Centre for Maternal, Adolescent, Reproductive and Child Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 16Department of Computer Science, University of Liverpool, Ashton Building, Ashton Street, Liverpool L69 3BX, UK.

17Department of International Public Health and Clinical Sciences, Liverpool School of Tropical Medicine and University of Liverpool, Liverpool, UK. 18Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MA, USA.

Received: 12 October 2018 Accepted: 30 January 2019 Published online: 06 March 2019

References
1. Krauss BS, Harakal T, Fleisher GR. The spectrum and frequency of illness presenting to a pediatric emergency department. Pediatr Emerg Care. 1991; 7(2):67–71.

2. Alpern ER, Henretig FM, Fever, Fleisher GR, Ludwig S. Textbook of pediatric emergency medicine. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 295–306.

3. Limper M, Eftekhari Schattenkerk D, de Kruif MD, van Wissen M, Brandjes DP, Duits AJ, et al. One-year epidemiology of fever at the emergency department. Netherlands. J Med. 2011;69(3):124–8.

4. Irwin AD, Drew RJ, Marshall P, et al. Etiology of childhood bacteremia and timely antibiotics administration in the emergency department. Pediatrics. 2015;135(4):635–42.

5. Gangoti I, Rodriguez E, Zubizarreta, et al. Prevalence of occult bacteremia in infants with very high fever without a source. Pediatr Infect Dis J. 2018;37:11.

6. Irwin AD, Grant A, Williams R, et al. Predicting risk of serious bacterial infections in febrile children in the emergency department. Pediatrics. 2017;140:2.

7. Mejer N, Westh H, Schenhedery HC, et al. Stable incidence and continued improvement in short-term mortality of Staphylococcus aureus bacteremia between 1995 and 2008. BMC Infect Dis. 2012;12:260.

8. Ladhani S, Pebody RG, Ramsay ME, et al. Continuing impact of infectious diseases on childhood deaths in England and Wales. 2005-2005. Pediatr Infect Dis J. 2010;29(4):310–3.

9. Wright C, Wordsworth R, Glennie L. Counting the cost of meningococcal disease: scenarios of severe meningitis and septicaemia. Paediatr Drugs. 2013;15(1):49–58.

10. Nijman RG, Vengouwe Y, Thompson M, van Veen M, van Meurs AH, van der Lei J, et al. Clinical prediction model to aid emergency doctors managing febrile children at risk of serious bacterial infections: diagnostic study. BMJ. 2013;346:f706.

11. Martín-Torres F, Salas A, Rivero-Calle I, et al. Life-threatening infections in children presenting to a pediatric emergency department. J Pediatr. 2013;162(6):1385–8.

12. Weddle G, Jackson MA. Sevranangan R. Reducing blood culture contamination in a pediatric emergency department. Pediatr Emerg Care. 2011;27(3):179–81.

13. Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics. 1999;104(1):79–86.

14. Bell JM, Shields MD, Aguas A, Dunlap K, Baurke T, Kee F, et al. Clinical and cost-effectiveness of procalcitonin test for prodromal meningococcal disease-a meta-analysis. PLoS One. 2015;10(6):e0128993.

15. Byington CL, Reynolds CC, Korgenski K, Shen X, Valentine KJ, Nelson RE, et al. Costs and infant outcomes after implementation of a care process model for febrile infants. Pediatrics. 2012;130(1):e16–24.

16. Schirger DL, Baraff LJ, Bailer K, Shendrikar MA, Nagda S, Lin EJ, et al. Implementation of clinical guidelines via a computer charting system: effect on the care of febrile children less than three years of age. J Am Med Inf Assoc. 2000;7(2):186–95.

17. Zachariajse JM, Seiger N, Rood PPM, Alves CF, Freitas P, Smit FJ, et al. Validity of the Manchester Triage System in emergency care: a prospective observational study. PLoS One. 2017;12(2):e0170811.

18. Herberg JA, Kafourou M, Wright VI, Shales H, Efthorhoinour H, Hoggart CJ, et al. Diagnostic test accuracy of a 2-transcript host RNA signature for discriminating bacterial vs viral infection in febrile children. JAMA. 2016;316(8):835–45.

19. Elifving K, Shakely D, Andersson M, Balzell K, Ali AS, Bachelard M, et al. Acute uncomplicated febrile illness in children aged 2–59 months in Zanzibar - aetiologies, antibiotic treatment and outcome. PLoS One. 2016;11(1):e0146054.

20. NHS Employers: Unsocial hours payments - Section 2(a) (England), 2017. Available at: http://www.nhsemployers.org/your-workforce/pay-and-reward/agenda-for-change/nhs-terms-and-conditions-of-service-handbook/unsocial-hours-payments. Accessed 8 Aug 2017.

21. GovUK NHS Reference Costs 2015/16. 2016. Available: https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016. Accessed 11 Apr 2017.

22. NICE CG160: Fever in under 5s: assessment and initial management, 2017.

23. Hardin JW, Hilbe JM. Generalized linear models and extensions. College Station: 2nd Stata Press; 2007.

24. Manning WK, Basu A, Mullaby J. Technical working paper 293: generalized modelling approaches to risk adjustment of skewed outcomes data. In: National Bureau of Economic Research, technical working paper series; 2003. http://www.nber.org/papers/t0293. Accessed 18 Feb 2016.

25. Briggs AH. Probabilistic analysis of cost-effectiveness: statistical representation of parameter uncertainty. Value in Health. 2005;8(1):1–2.

26. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. 3rd ed. Oxford: Oxford University Press; 2006.

27. NICE NG51: Sepsis recognition, diagnosis and early management, 2017.

28. Ketel K, Alcoba G, Lacroix L, Manzano S, Galetto-Lacour A, Gervaix A. Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva, Switzerland. Swiss Med Wkly. 2014;144:w13925.

29. Gunduz S, Usak E, Koksal T, Canbal M. Why fever phobia is still common? Iran Red Crescent Med J. 2016;18(8):e23827.

30. Crocetti M, Moghbeli N, Serventi J. Fever phobia revisited: have parental misconception about fever changed in 20 years? Pediatrics. 2001;107(6):1241–6.

31. Elkon-Tamir E, Rimon A, Sculkin D, Glatstein M. Fever phobia as a reason for pediatric emergency department visits: does the primary care physician make a difference? Rambam Maimonides Med J. 2017;8(1). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298368/.

32. Nickovic LE, Mahajan PV, Blumberg SM, et al. The Yale Observation Scale score and the risk of serious bacterial infections in febrile infants. Pediatrics. 2017; 140: np.

33. Bang A, Chaturvedi P. Yale Observation Scale for prediction of bacteremia in febrile children. Indian J Pediatr. 2009;76(6):599–604.

34. Thompson M, Van den Bruel A, Verbakel J. Systematic review and validation of prediction rules for identifying children with serious infections in emergency departments and urgent-primary care. Health Technol Assess. 2012;16(15):1–100.

35. Wilkes JJ, Leckerman KH, Coffin SE, Keren R, Metjian TA, Hodinka RL. Use of antibiotics in children hospitalized with community-acquired, laboratory-confirmed influenza. J Pediatr. 2009;154(4):447–9.

36. Hamden A, Pereira R, Rueggemm AB, Mayon-White R, Crook DW, Thomson A, et al. Respiratory infections for which general practitioners consider prescribing an antibiotic: a prospective study. Arch Dis Child. 2007;92(7):594–7.

37. Bryce A, Hay AD, Lane IF, Thornton HV, Wootton M, Costelloe C. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ. 2016;352:i2039.

38. van Veen M, Steyerberg EW, Ruige M, van Meurs AH, Roukema J, van der Lei J, et al. Manchester triage system in paediatric emergency care: prospective observational study. BMJ. 2008;337:a1501.

39. Santos AP, Freitas P, Martins HM. Manchester Triage System version II and resource utilisation in the emergency department. J Emerg Med. 2014;31(2):148–52.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions